Keros TherapeuticsvsEli Lilly and Company

KROS and LLY stock compared: price, dividend, valuation and results, from SEC filings.

KROS

Keros Therapeutics, Inc.

$12.00

Value $237M

+6.10%
KROS's page

LLY

Eli Lilly and Company

$1,382.75

Value $1.30T

-2.32%
LLY's page

Keros Therapeutics (KROS) has a market value of $237M and Eli Lilly and Company (LLY) $1.30T. Over the last year, with dividends, KROS moved -30.9% and LLY +36.2%. Dividend yield: KROS none, LLY 0.46%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KROS$237M

    LLY$1.30T

    LLY is 5,513 times KROS

  • Revenue, 12 months

    KROS$41M

    LLY$86.5B

    LLY is 2,121 times KROS

  • Net income, 12 months

    KROS-$62M

    LLY$27.6B

  • Operating margin

    KROS-179.8%

    LLY–

  • ROIC

    KROS-15.8%

    LLY35.5%

    51.3 points apart

  • P/E

    KROS–

    LLY47.3

  • Dividend yield

    KROS0.0%

    LLY0.5%

    0.5 points apart

  • 5-year return

    KROS-80.2%

    LLY+452.8%

    533.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KROS-80.2%

LLY+452.8%

020040060020222023202420252026
Returns by period
PeriodKROSWith dividendsLLYWith dividends
1 year since November 17, 2025-30.9%Price -30.9%+36.2%Price +35.3%
3 years since November 17, 2023-60.4%-26.5% a yearPrice -60.4%+138.4%+33.6% a yearPrice +133.7%
5 years since November 17, 2021-80.2%-27.7% a yearPrice -80.2%+452.8%+40.8% a yearPrice +429.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KROSKeros TherapeuticsLLYEli Lilly and Company

Valuation

KROSLLY
Valuation
Price$12.00$1,382.75
Market value$237M$1.30T
Enterprise value (EV)–$1.35T
P/E–47.3
P/E, 5-year median–49.9
P/B0.932.4
EV/EBIT–38.8
Free cash flow yield–1.5%

Results and growth

KROSLLY
Results and growth
Revenue, 12 months$41M$86.5B
Net income, 12 months-$62M$27.6B
Free cash flow, 12 months-$48M$19.7B
Earnings per share, 12 months-$2.34$30.81
Revenue growth, year on year6,775.0%44.7%
Revenue growth a year, past–+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

KROSLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin-179.8%–
Net margin-151.4%31.9%
ROIC-15.8%35.5%
ROE-16.8%88.6%

Balance sheet

KROSLLY
Balance sheet
Cash$259M$4.9B
Total debt$15M$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

KROSLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield158.5%0.3%
Shareholder yield158.5%0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KROS or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Keros Therapeutics or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.30T) is about 5,513.0 times Keros Therapeutics ($237M), at today's prices.

How did KROS and LLY stock do over the last 5 years?

Since November 17, 2021, KROS's price moved -80.2% and LLY's +429.4%. With dividends: KROS -80.2% (-27.7% a year), LLY +452.8% (+40.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, KROS or LLY?

The dividend yield at today's price is none for Keros Therapeutics and 0.46% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Keros Therapeutics or Eli Lilly and Company?

Over the last twelve months, the net margin was -151.4% for Keros Therapeutics and 31.9% for Eli Lilly and Company, and the operating margin -179.8% and –. Revenue was $41M and $86.5B.

Which is the better investment, Keros Therapeutics or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.